From Paternalism to Autonomy was the subject of the 33rd annual meetingof the European Propriety Medicines Manufacturers' Association, held in Budapest, Hungary, this month. The conference was kicked off by AESGP president Hugues Lanrezac, who told delegates that it was not enough just to make medicines available without prescription; it is necessary to ensure that consumers are made aware of the availability.
Political recognition is a good basis for self-medication, according to Mr Lanrezac, but we have to change the rules and reduce differences in legislation among the European countries. Guidelines on classification have now been accepted, but the over-the-counter drugs industry still needs changes on the use of universal brand names, he said.
Regulatory authorities, he stressed, have to be convinced that products switching from prescription-only status to OTC need to retain the same brand names. This was an issue also taken up by Hans Regenauer, vice president of Spain's OTC drugmakers' association, the ANEFP.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze